In AD patients, TREM2 variants with reduced amyloid binding affinity are associated with increased AD risk [211, 213–215], and human stem-cell-derived microglia-like cells lacking TREM2 show markedly decreased amyloid β uptake [216]. The gene discussed is TREM2; the disease is Alzheimer disease.